Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 259 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intravitreal Injection Clear all
Completed Phase 1 Interventional

A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD

NCT00536016
View directory record Official record
Conditions
Macular Degeneration
Interventions
JSM6427
Drug
Lead sponsor
Jerini Ophthalmic
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Beverly Hills, California • Boston, Massachusetts • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

NCT03034772
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
Dorzolamide-timolol, Artificial tears
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
45 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 21, 2026, 5:08 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 21, 2026, 5:08 PM EDT
Recruiting Phase 3 Interventional

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
60
States / cities
Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

NCT00140803
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Visudyne, Kenalog
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2007 · Synced Oct 21, 2026, 5:08 PM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

NCT00695318
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
55 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 1 Interventional

Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

NCT00685854
View directory record Official record
Conditions
Macular Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 5:08 PM EDT
Withdrawn Phase 4 Interventional

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

NCT03059277
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Aflibercept
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

NCT05161806
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
Drug · Device
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 1 Interventional

Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

NCT00722384
View directory record Official record
Conditions
Macular Degeneration
Interventions
bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2008 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

NCT02949024
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
IVT Aflibercept, SC CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Mountain View, California • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

NCT03930641
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
RTH258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Altamonte Springs, Florida • Pensacola, Florida • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525613
View directory record Official record
Conditions
Geographic Atrophy
Interventions
APL-2, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
67
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 21, 2026, 5:08 PM EDT
Not listed Phase 1 Interventional

Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms

NCT02403128
View directory record Official record
Conditions
Macular Edema, Retinal Artery Macroaneurysm
Interventions
aflibercept
Drug
Lead sponsor
Kamal Kishore, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 1 Interventional

Intravitreal Aflibercept Injection for Radiation Retinopathy

NCT01579760
View directory record Official record
Conditions
Radiation Retinopathy, Macular Edema
Interventions
Aflibercept every 2 months, Aflibercept monthly
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

NCT00798317
View directory record Official record
Conditions
Vitreomacular Adhesion
Interventions
Ocriplasmin 125µg, Placebo
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Campbell, California • San Francisco, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 1 Interventional

Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

NCT00886808
View directory record Official record
Conditions
Diffuse Diabetic Macular Edema
Interventions
iCo-007 Intravitreal Injection
Drug
Lead sponsor
iCo Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 2 Interventional

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106
View directory record Official record
Conditions
Glaucoma, Angle-closure, Primary, Acute
Interventions
QPI-1007 Injection, (including placebo)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Orange, California • Pasadena, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 4 Interventional Results available

Control of Pain in Intravitreal Injections Using Topical NSAIDs

NCT04343222
View directory record Official record
Conditions
Intravitreal Injections, IVI
Interventions
Bromfenac, Artificial tears
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 21, 2026, 5:08 PM EDT
Withdrawn Not applicable Interventional

Intravitreal Gas for Vitreomacular Adhesion

NCT02001701
View directory record Official record
Conditions
Vitreomacular Adhesion
Interventions
Intravitreal Injection of sulfahexafluoride gas
Procedure
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

NCT00470977
View directory record Official record
Conditions
Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions
ranibizumab injection (0.5 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Not applicable Interventional

Long Term Safety of Cooling Anesthesia for Intravitreal Injection

NCT03956797
View directory record Official record
Conditions
Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Recens Cooling Anesthesia Device
Device
Lead sponsor
Recens Medical, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Reno, Nevada • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 21, 2026, 5:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Vonaprument, Sham Administration
Drug · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

NCT00412958
View directory record Official record
Conditions
Vitrectomy
Interventions
Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg, Placebo
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Tucson, Arizona • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 21, 2026, 5:08 PM EDT